Clinical Research

Bayer AG

Address
-

Sponsor Overview

assignment
73
sponsored trials
science
35
molecules
location_city
987
research centres
public
23
countries
person_search
1808
investigators

Specializations

Oncology and Molecularly Targeted Cancer Care

Non-small cell lung cancer, solid tumors, and prostate cancer are prominent areas of interest, including disease settings defined by EGFR, HER2, NTRK fusion, KRAS G12C, and MTAP deletion. Research also extends to hepatocellular carcinoma and metastatic disease.

  • Advanced solid tumors
  • HER2-mutated cancers
  • Metastatic castration-resistant prostate cancer
  • NTRK-fusion malignancies

Interest includes both precision oncology and treatment strategies for advanced, refractory, and biomarker-defined cancers.

Cardiovascular, Thrombotic, and Hemostatic Disorders

The sponsor is active in atrial fibrillation, ischemic stroke, transient ischemic attack, deep vein thrombosis, and thromboembolic events, along with coronary artery disease and cardiac arrhythmia. Studies also cover coagulopathy and hemophilia A.

  • Stroke prevention
  • Atrial fibrillation
  • Thrombosis and clot lysis
  • Hemophilia A

Additional cardiovascular work includes vasodilatory shock, arterial hypertension, and heart failure across adult and pediatric populations.

Kidney Disease and Cardiorenal Syndromes

Research activity includes chronic kidney disease, proteinuria, Alport syndrome, and kidney involvement in type 1 diabetes mellitus and type 2 diabetes mellitus. The portfolio also addresses heart failure with reduced ejection fraction and left ventricular systolic dysfunction in cardiorenal disease.

  • Chronic kidney disease
  • Alport syndrome
  • Proteinuria
  • Heart failure with kidney involvement

There is also interest in pediatric chronic kidney disease and renal complications associated with inherited and metabolic disorders.

Ophthalmology and Retinal Vascular Disease

The sponsor supports studies in diabetic macular edema, neovascular age-related macular degeneration, and macular edema secondary to retinal vein occlusion. Pediatric eye disease is also represented through retinopathy of prematurity.

  • Diabetic macular edema
  • Neovascular age-related macular degeneration
  • Retinal vein occlusion
  • Retinopathy of prematurity

Imaging-related work includes contrast-enhanced magnetic resonance imaging for central nervous system and non-central nervous system assessment.

Pulmonary Vascular Disease, Menopause, and Infectious Disease

Additional research spans pulmonary arterial hypertension, pulmonary hypertension due to left heart disease, and pulmonary hypertension associated with interstitial lung disease. The portfolio also includes vasomotor symptoms and sleep disturbances associated with menopause.

  • Pulmonary hypertension
  • Menopausal vasomotor symptoms
  • Sleep disturbances in menopause
  • Onchocerciasis

In infectious disease, the sponsor is involved in studies on onchocerciasis and soil-transmitted helminth infection, reflecting interest in parasitic disease.

Sponsored Trials

Trial Name Country Status
(20289) A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive TumorsDenmark DenmarkFrance FranceGermany GermanyPortugal PortugalSpain SpainSweden SwedenNot Recruiting
(20290) A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients with Advanced Solid or Primary Central Nervous System TumorsCzechia CzechiaDenmark DenmarkFrance FranceGermany GermanyIreland IrelandItaly ItalySpain SpainSweden SwedenThe Netherlands The NetherlandsNot Recruiting
(21140 ARANOTE) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC).Latvia LatviaLithuania LithuaniaSpain SpainNot Recruiting
(21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs)Bulgaria BulgariaCzechia CzechiaFrance FranceGermany GermanyHungary HungaryItaly ItalySweden SwedenNot Recruiting
(21196) A multicenter, prospective, open-label study to evaluate the pharmacokinetics and safety of gadoquatrane in pediatric participants (from birth to <18 years) undergoing contrast-enhanced magnetic resonance imaging (CE-MRI)Bulgaria BulgariaCzechia CzechiaGermany GermanyHungary HungaryPoland PolandSweden SwedenNot Yet Recruiting
(21197) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs)Bulgaria BulgariaCzechia CzechiaFrance FranceGermany GermanyHungary HungaryItaly ItalyPoland PolandSweden SwedenNot Recruiting
(21466) A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD)Austria AustriaBelgium BelgiumBulgaria BulgariaCzechia CzechiaFinland FinlandGermany GermanyGreece GreeceHungary HungaryItaly ItalyPoland PolandPortugal PortugalSpain SpainSweden SwedenRecruiting
(21467) A Phase 3, single-arm, open-label extension study to evaluate the safety of finerenone in addition to standard of care, in pediatric heart failure patients, from birth to 18 years of age, with left ventricular systolic dysfunction (LVSD)Austria AustriaBelgium BelgiumBulgaria BulgariaCzechia CzechiaFinland FinlandGermany GermanyGreece GreeceHungary HungaryItaly ItalyPoland PolandPortugal PortugalSpain SpainSweden SwedenRecruiting
(21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancerAustria AustriaBelgium BelgiumCzechia CzechiaDenmark DenmarkFinland FinlandFrance FranceGermany GermanyHungary HungaryItaly ItalyPoland PolandPortugal PortugalSpain SpainSweden SwedenThe Netherlands The NetherlandsNot Recruiting
(21751) First-in-human single dose escalation study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of BAY 3018250 in healthy men in a randomized, placebo-controlled, single-blind, group-comparison designGermany GermanyNot Recruiting
1–10 of 73
1 / 8

Data & Insights

science
Molecule Portfolio
Compounds under investigation
5
Exclusive Molecules
out of 35 total (14% not shared with other sponsors)

This sponsor works with 35 molecules, of which 5 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
38%
Return partnership rate
376 of 987 sites collaborated multiple times

This sponsor has worked with 987 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Cardiovascular Diseases32 trials
    359 other sponsors
  • 2.
    Neoplasms17 trials
    853 other sponsors
  • 3.
    Hormonal diseases4 trials
    89 other sponsors
  • 4.
    Diagnosis3 trials
    83 other sponsors
  • 5.
    Eye Diseases3 trials
    138 other sponsors
  • 6.
    Nutritional and Metabolic Diseases3 trials
    211 other sponsors
  • 7.
    Congenital, Hereditary, and Neonatal Diseases and Abnormalities2 trials
    165 other sponsors
  • 8.
    Female Urogenital Diseases and Pregnancy Complications2 trials
    142 other sponsors
  • 9.
    Hemic and Lymphatic Diseases2 trials
    249 other sponsors
  • 10.
    Parasitic Diseases2 trials
    9 other sponsors
  • 11.
    Male Urogenital Diseases1 trial
    111 other sponsors
  • 12.
    Not possible to specify1 trial
    220 other sponsors
  • 13.
    Respiratory Tract Diseases1 trial
    277 other sponsors

Partnered Research Centres

987 centres
location_city
assignment32
1 Wojskowy Szpital Kliniczny Z Poliklinika samodzielny publiczny zakład opieki zdrowotnej W Lublinie
Address
Ul. Aleje Raclawickie 23, 20-049 Lublin
Learn morearrow_forward
location_city
assignment23
401 General Military Hospital Of Athens
Address
Panagioti Kanellopoulou Av 1, 115 25 Athens
Learn morearrow_forward
location_city
assignment3
A Z Monica
Address
Florent Pauwelslei 1, 2100 Antwerp
Learn morearrow_forward
location_city
assignment22
A.O. Krankenhaus St. Josef Braunau GmbH
Address
Ringstraße 60, 5280 Braunau am Inn
Learn morearrow_forward
location_city
assignment103
A.O.U. Policlinico G. Martino Di Messina
Address
Via Consolare Valeria N 1, 98124 Messina
Learn morearrow_forward
location_city
assignment1
A.ö. Landeskrankenhaus Hall
Address
Milser Straße 10, 6060 Hall in Tirol
Learn morearrow_forward
Page 1 of 165

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Bayer AG.

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.